It's encouraging news for people trying to lose weight safely, especially older adults who want to drop pounds without losing bone or muscle mass. The study, "Does time spent upright moderate the influence of a weighted vest on change in bone mineral density during weight loss among older adults," appears in the peer-reviewed journal Frontiers in Aging. Weighted vests can provide an external load equal to the amount of weight lost. Help the body prevent metabolic slowdown, assisting with weight-loss maintenance. Preserve muscle and bone, which is particularly important as we age. Researcher Jason Fanning, lead author of the study and associate professor of health and exercise science, analyzed data from Wake Forest University's INVEST in Bone Health for this study. The randomized, controlled trial led by Wake Forest colleague Kristen Beavers looked at whether wearing a weighted vest could help preserve bone mineral density during one year of weight loss. Participants were divided into three groups, and the weighted vest group wore the vest at least eight hours each day. Weighted vest plus weight loss group: More time spent standing or stepping yielded positive changes in bone mineral density. Weight loss alone group: Standing or stepping more often showed negative changes in bone mineral density. Weight loss plus resistance training group: Time spent upright didn't influence bone mineral density. It will explore whether encouraging people to move more often boosts a weighted vest's effectiveness in preserving bone mass. "If we're going to be putting vests on people, we need to train those people to be up and moving," said Fanning, who also is a primary investigator in a current study looking at how movement affects pain from arthritis. But, like any tool, it's not going to do the work for you." Fanning, J., et al. (2026) Does time spent upright moderate the influence of a weighted vest on change in bone mineral density during weight loss among older adults? A secondary analysis of the INVEST in bone health randomized controlled trial. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Increased serum antibody response to commensal Lachnospiraceae flagellins appears to be preclinically associated with future risk for Crohn's disease (CD) in healthy first-degree relatives (FDRs) of CD patients, a new study confirmed. Pre-CD immunoglobulin G (IgG) seroreactivity toward a conserved bacterial flagellin epitope may be another early preclinical biomarker of CD, a study by Canadian, US, and Israeli researchers published in Clinical Gastroenterology and Hepatology confirmed. The findings add more evidence of early inflammatory markers long before CD diagnosis. Whip-like proteins on the surface of bacteria, flagellins propel the bacteria around their environment in search of new habitats to colonize and new food sources, and they play a role in immune mediation. “Although prior studies showed that antimicrobial antibodies can appear years before diagnosis, it was unclear which immune responses were most informative or biologically meaningful.” The group's earlier published research had also suggested that elevated antimicrobial antibody responses are associated with CD risk, independent of usual biomarkers of abnormal gut barrier function, subclinical inflammation, and related genetic risks. This strengthened the idea that such responses are an early predisease event in CD. Confirming their previous study, immune responses against bacterial flagellins — especially those of the anaerobic gut bacterium Roseburia hominis— were strongly associated with future CD risk in FDRs on average about 2.5 years before diagnosis. “The flagellin epitope is an attractive candidate for a future preventive vaccine, but there are still plenty of unknown variables that need to be tested first,” study coauthor Williams Turpin, PhD, a translational research scientist and an assistant professor in the University of Toronto Temerty Faculty of Medicine's Medical Department of Nutritional Sciences, told Medscape Medical News. As to why certain individuals develop antibodies against this epitope before CD onset, Turpin said, “It could be a lack of immune tolerance, or that the flagellin peptide tends to translocate much more easily as a result of defects in barrier function. Resources permitting, should all healthy FDRs of CD patients now be tested? “Testing for the presence of this epitope could identify individuals who are even higher risk. First, however, there needs to be an understanding of the succession of events that lead to the increase in antibodies against this specific flagellin epitopes so that interventions can perhaps prevent pathogenesis, Lee cautioned. Added co-senior author Ken Croitoru, MD, “With all the advanced biologic therapy we have today, patients' responses are partial at best. The current analysis monitored a nested case-control cohort of FDRs who later developed CD (n = 77). The median age of probands was 15 years (interquartile range, 12-21), 58.4 were female, and 80.5% were siblings rather than offspring, suggesting the influence of shared early-life environmental experience. CD patients were matched with healthy FDRs (n = 304) in a 1:4 ratio by age, sex, follow-up duration, and geographic location. Conditional logistic regression was used to evaluate the association with CD onset, and a partial Spearman test was used to correlate serologic responses with variables such as lactulose-to-mannitol ratio (LMR), C-reactive protein, and fecal calprotectin (FCP). “An ELISA [enzyme-linked immunosorbent assay] test could be used in future clinical settings given its low cost and rapid turnaround,” Lee said. These IgG-seroreactive flagellins shared significant amino acid sequence homology, characterized by a conserved flexibility-linked hinge peptide within the D0-D1 domains of the amino terminus. A cytometric bead array confirmed the association of elevated IgG seroreactivity to the hinge peptide with future CD risk, independent of LMR and FCP. Ashwin N. Ananthakrishnan, MBBS, MD, MPH, a clinician investigator at Mass General Research Institute and an associate professor at Harvard University in Boston who was not involved in the study, told Medscape Medical News, “This is an important study that builds on prior work from this group and others demonstrating that there exists a subclinical period in some patients who develop CD even many years before diagnosis.” Ananthakrishnan cautioned, however, that the test is far from ready for prime time because while studies have established that informative at-risk markers exist, no interventions have yet been shown to prevent disease. “We still don't know whether it's limited, immunologically directed medical treatment, microbiome-based treatment, or lifestyle-based treatment such as diet that will be effective and acceptable to healthy patients who do not yet have a disease — not to mention the lack of data on the duration that such interventions would be necessary.” Further validation and mechanistic studies are underway at Mount Sinai. Coauthor Elson reported a patent on Lachnospiraceae A4 Fla2, licensed by Prometheus Laboratories.

Refeyn, developer of pioneering mass photometry technology, expands its global adoption across contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Introduced just eight years ago, the technology is now cited in nearly 1,500 scientific publications and is used by 90 % of top biopharma companies. With GMP-compliant software for AAV analytics and recognition from regulatory bodies – including the US Pharmacopeia, China's NIFDC, and the British Pharmacopeia – mass photometry can be deployed confidently from early development through manufacturing and QC. This enables clients to make earlier, better-informed development decisions while reducing sample consumption and turnaround times, tackling analytical challenges that are difficult with traditional methods. Adding mass photometry to the analytical panel reduces the overall cost of new therapies by accelerating development and manufacturing, By working with partners around the world, we're expanding access to this technology – whether organizations invest in their own instruments or use trusted service providers – ultimately helping shorten the path from discovery to patients." Gabriella Kiss, PhD, Director of Market Development, Refeyn CROs and CDMOs can partner with Refeyn to differentiate their analytics and meet growing demand for faster, higher-quality data, while biopharma teams can access mass photometry through the expanding partner network. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Bedfont® Scientific Limited, a well-established Med-Tech company with over 49 years of expertise in the design and manufacture of medical breath analysis devices, is celebrating the women driving innovation in the Med-Tech industry this International Women's Day (IWD). IWD is an annual event that celebrates women's achievements and raises awareness about gender equality. This year's theme, ‘Give to gain', highlights the power of reciprocity and support. By giving women equal access to leadership opportunities, Bedfont® has built a diverse and balanced team. Today, women make up 50 % of the workforce and nearly half of the companies' 18 managers, proof that inclusion creates tangible gains for people and performance alike. However, research published in 2024 shows that among the 78 largest medical device companies in Europe, only 24.4 % of leadership positions are held by women, highlighting the ongoing need for greater gender equality at senior levels. In a world where women in business have far greater opportunities than in our ancestors' time, we are now seeing women actively driving the future of MedTech through innovation, leadership and scientific excellence. I am incredibly proud that nearly half of the leadership team at Bedfont are women, clear evidence that inclusion fuels both performance and progress. Representation matters, not only within our industry but for the next generation watching. As a mother of two daughters, I want them to grow up proud, strong and confident enough to make their own mark in science, technology and beyond. On this International Women's Day, with this year's theme “Give to Gain,” we recognize that by investing in, training and championing women, we are shaping the future of MedTech and creating lasting impact for generations to come.” This International Women's Day, Bedfont® is celebrating the strength of a balanced workforce by recognising the women across the organization with sustainably sourced chocolate from local business N2 Sweets Lab. This initiative reflects the company's broader commitment to sustainability while supporting both local businesses and third-party partners worldwide, reinforcing a give-to-gain approach that benefits people, communities, and the planet. Please use one of the following formats to cite this article in your essay, paper or report: Giving opportunity, gaining innovation: Women driving the future of Med-Tech. Bedfont® Scientific Ltd. "Giving opportunity, gaining innovation: Women driving the future of Med-Tech". Bedfont® Scientific Ltd. "Giving opportunity, gaining innovation: Women driving the future of Med-Tech". Giving opportunity, gaining innovation: Women driving the future of Med-Tech. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Coronaviruses not only use the machinery of the human cells they infect: they modify it to achieve optimal conditions to produce viral proteins and thus spread more quickly. This is the main conclusion of a study by Pompeu Fabra University published in Nature Communications. The study identifies enzymes that modify transfer RNAs (tRNAs) –small cellular parts required to build proteins– as key elements for coronavirus infection. These enzymes are activated by the stress response of viral infection and could be a new therapeutic target for developing broad-spectrum antiviral drugs against coronaviruses. "Coronaviruses are very dangerous because of their ability to generate new variants capable of infecting humans after circulating in animal reservoirs", explains Juana Díez, director of the Molecular Virology Research Group at Pompeu Fabra University, who led the research. At present we do not have any broad-spectrum antiviral drugs that are effective against coronaviruses. Juana Díez, Director, Molecular Virology Research Group, Pompeu Fabra University For this reason we asked ourselves how a virus can spread so quickly within a cell where the tRNAs it needs to make its viral proteins are not abundant", outlines Elena Muscolino, first author of the study. Coronaviruses have taken advantage of this situation, since "in order to manufacture stress response proteins, the same tRNAs that coronaviruses need to manufacture their viral proteins are needed", explains Mireia Puig, also an author of the work. This readjustment, driven by cellular enzymes that modify tRNAs, allows coronaviruses to speed up the production of their proteins without the need to generate new machinery, simply by altering the existing one. "Since changes in tRNAs are modifications of the machinery that the cell already has and not the generation of new "cell parts", viral protein production occurs rapidly and coronaviruses can spread very quickly", Muscolino points out. The modification of tRNAs has been observed both in SARS-CoV-2, associated with serious infections, and in HCoV-OC43, which usually causes very mild cold-like signs and symptoms. Therefore, it could be a common strategy among different coronaviruses. In addition, when the activity of these modifying enzymes is blocked, viral protein production decreases significantly. "The tRNA-modifying enzyme is a promising candidate for developing broad-spectrum antiviral drugs capable of curbing the spread of coronaviruses", Díez states. And she adds: "A drug of this type would allow us to contain the infections caused by new coronaviruses from their initial phases and prevent their rapid expansion, and therefore, new pandemics". Coronaviruses reprogram the tRNA epitranscriptome to favor viral protein expression. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A new study of what families think about virtual reality (VR) technologies reveals that parents want more research-based information on how VR technologies may influence brain and behavioral development. "We know that families have concerns about whether it is appropriate for children and teenagers to use VR technologies, but there has been little research done on how families prioritize those concerns or how they can be addressed," says Qiao Jin, first author of a paper on the work and an assistant professor of computer science at North Carolina State University. That's what we were setting out to explore with this work." For the study, researchers began by analyzing interview data from 67 children and 55 adult guardians. The interview process explored issues related to the many factors that come into play regarding how families make decisions about VR use, as well as who families feel should be responsible for addressing family concerns about VR use. The researchers then compiled those interview responses and convened a focus group of 84 children and 40 guardians, asking them to rank the responses from each category: what information was most important, what sort of content is most appealing to families, and so on. One key finding was that families wanted more information regarding brain and behavioral development. Families felt these things were foundational concerns that could influence a range of other issues, such as a child's ability to learn and form relationships with peers. "Rather than treating brain and behavior separately, participants often discussed them as deeply interconnected, affecting everything from learning to relationships to happiness," Jin says. "Study participants felt a better understanding of how VR may affect the brain and behavior also informed their understanding of VR's influence on screen time and usage frequency at a deeper level. One surprising finding was that families prioritized physical activity over other features with regard to what makes a VR platform more attractive Family views on who should be responsible for addressing VR concerns were more complicated. "Instead, study participants envisioned a model of governance where industry would build VR platforms; university research would evaluate those platforms and study how VR affects children; and public institutions - including doctors, teachers and other domain experts - would use that information to make evidence-based decisions designed to guide the use of VR platforms and protect kids. "One clear take-away from this work is that more needs to be done to deepen our understanding of how VR use may affect brain and behavioral development in children, so that we can share this information with parents and families," says Jin. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Azenta, Inc. today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The transaction is expected to close on or before March 31, 2026. The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact, The proceeds from this sale will be deployed to strengthen the company and drive long-term profitable value creation for our shareholders.” John Marotta, President and CEO, Azenta Life Sciences B Medical Systems is a global manufacturer and distributor of medical refrigeration devices based in Luxembourg. William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel to Azenta for this transaction. Please use one of the following formats to cite this article in your essay, paper or report: Azenta enters definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L.. News-Medical. "Azenta enters definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L.". "Azenta enters definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L.". Azenta enters definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L.. News-Medical, viewed 03 March 2026, https://www.news-medical.net/news/20260302/Azenta-enters-definitive-agreement-for-the-sale-of-its-B-Medical-Systems-business-to-THELEMA-SA-RL.aspx. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please read and accept to continue. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Neuropathy – chronic pain, numbness and tingling in the hands and feet – is a challenging fact of life for many patients with Type 1 diabetes. Thanks to a new National Institutes of Health grant, a University of Central Florida (UCF) College of Medicine scientist is investigating a new approach to treat neuropathy without relying on pain pills and anti-depressants. People affected by Type 1 diabetes don't produce insulin, the hormone that regulates blood sugar, so patients must inject themselves with insulin to survive. Before joining UCF, Dr. Nichols spent many years looking for new causes of diabetic neuropathy. One of the challenges of living with diabetes is that patients with neuropathy may lose feeling in their extremities and not feel a cut, blister or injury. Those injuries can become infected and even lead to amputation. Such diabetic complications occur more frequently in patients with poor blood sugar control, so Dr. Nichols is hoping that his research will find a treatment to regulate and improve neuron signaling that can be used as part of improved blood sugar management. "We're diving into an area that's fresh," he said. During the next three years, Dr. Nichols and his team will document the behavior of neurons, their signaling systems and surrounding cells to find ways to regulate them to alleviate symptoms of neuropathy. While approved therapeutics such as opioids and antidepressants can curb those symptoms, Dr. Nichols hopes his investigational treatment can become a more viable alternative for diabetic patients. "There are typical pain therapies out there, although we're trying to move away from that because diabetic neuropathy isn't very amenable to the basic treatments that we have," he said. "We're trying to find better therapies, and that is our goal." Dr. Nichols arrived at UCF in the summer of 2025, and said his goal is to inspire students to pursue bold new research directions. "One of the things I tell the students is that we fail fast and we fail safe here," he said. Now pursuing a Ph.D. in biomedical sciences, she joined Dr. Nichols' lab because she wants to help patients like her parents, who both suffered from diabetes. "This is personal to me because my mom was diabetic and she died from complications with it," Akaniru said. "My dad now is showing signs of peripheral neuropathy. There are treatments for other comorbidities of diabetes, but I think it could go a long way to have something that could really help neuropathic pain better." During her time at UCF, she worked on research to fight pediatric tumors and still carries that inspiration today. "It got me really interested in focusing on helping people who are just suffering with chronic, debilitating pain, and especially anything that comes with nerves," Hayes said. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A new retrospective cohort study examining the impact of Minnesota's first-in-the-nation mandated universal newborn screening for congenital cytomegalovirus (cCMV) shows that universal screening significantly decreased the age at first audiology visit and increased identification of mild hearing loss in infants. The findings, published in Otolaryngology–Head and Neck Surgery, the peer-reviewed journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), add to a growing body of evidence supporting universal cCMV screening programs as a critical public health tool. Congenital cytomegalovirus is the leading infectious cause of birth defects and the leading non-genetic cause of hearing loss in infants, affecting approximately 1 in every 200 newborns. CMV-related hearing loss can be progressive, with over 55% of both asymptomatic and symptomatic children developing hearing loss after the newborn period. The narrow therapeutic window for antiviral treatment-most effective when initiated within the first month of life-makes early identification through universal screening essential for ensuring timely intervention. "Our experience in Minnesota shows that universal screening for cCMV enhances our ability to catch mild hearing loss early on in life and has the potential to improve the life of children who are diagnosed with the disease. Our hope is that our experience in Minnesota will guide policymakers in other states as we continue to learn more about cCMV and the best way to screen for and treat this common condition," said Andrew J. Redmann, MD, Assistant Professor in the Department of Otolaryngology–Head and Neck Surgery at the University of Minnesota Medical School and Children's Minnesota. Researchers examined 132 patients diagnosed with cCMV at Children's Minnesota between 2021 and 2024, comparing outcomes before, during, and after the rollout of universal screening. "The evidence from Minnesota's pioneering program-and from studies across the country-overwhelmingly supports universal screening," said Rahul K. Shah, MD, MBA, AAO-HNS/F Executive Vice President and CEO. Senators Richard Blumenthal (D-CT), Roger Marshall, MD (R-KS), and Mark Kelly (D-AZ), thanks to the efforts of AAO-HNS working in partnership with other key allies and medical societies. This important legislation would authorize federal funding for cCMV screening programs that improve early detection and intervention of hearing loss in infants. New York: The Academy submitted a letter to the New York State Legislature in strong support of Assembly bills A.3956 and A.3074, which would establish universal newborn CMV screening and require reporting of positive results to ensure timely referral and coordinated follow-up care. Dr. MacArthur urged OHA to include otolaryngology as a first-line referral for infants with confirmed cCMV and emphasized the role of telehealth in reaching rural and underserved families. Vermont: AAO-HNS submitted a letter to the Vermont House Committee on Human Services in strong support of H.533, legislation that would require the Department of Health to add cCMV to the newborn screening panel, provide education for expectant parents and healthcare providers, and create a multidisciplinary advisory committee to support coordinated, evidence-based implementation. Massachusetts: The Academy submitted testimony in support of H. 4367, which would require universal cCMV screening for all newborns, establish a statewide public education program, and create an advisory committee to guide implementation and ensure equitable access. Looking ahead: Several additional states are expected to move forward with cCMV screening proposals soon, including Michigan, Illinois, and Vermont. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

New research from the University of Oregon finds that those fluctuations don't change a woman's ability to exercise hard, but they do influence how difficult that work feels. Women have historically been very understudied in physiology, and especially exercise physiology, and even more so across our menstrual cycle." Many studies comparing exercise and female hormone levels have focused on the early follicular phase of the menstrual cycle, between the onset of bleeding up until ovulation, Schoeberlein said. (Men also produce low levels of progesterone and estrogen hormones). But those studies don't capture the effects of estrogen and progesterone rising and falling throughout the menstrual cycle. Schoeberlein wanted to know how those changes affect an athlete's ability to maintain intense exercise under a specific threshold known as the maximal metabolic steady state. The boundary between sustainable and unsustainable exercise is particularly important for athletes because it's an ideal spot to train in. Elite marathon runners, for example, run their races just below that threshold. "That [threshold] can be a very important performance indicator because if you're exercising above it, you cannot sustain exercise for very long," said Brad Wilkins, the director of the Oregon Performance Research Lab and an assistant professor of human physiology. For four weeks, participants came in weekly to use a stationary bike, biking at progressively harder levels during their workout. Before each session, participants had their hormone levels measured using a blood sample. Throughout the session Schoeberlein measured various biological benchmarks such as heart rate, oxygen uptake and carbon dioxide production. Participants also reported how difficult their workout felt afterward. "That ability to go and work is still at the same level across the whole menstrual cycle," Schoeberlein said. Interestingly, it was the self-reported data that changed. The team also found that both men and women were able to do similar intensities of work, after accounting for differences in total muscle mass. "What you can sustain appears to be the same across the menstrual cycle, but how it feels might be different," Schoeberlein said. It's also one of the few that included participants using multiple types of birth control, including IUDs and oral contraceptives. The results underscore that there's no one-size-fits-all approach to training, Schoeberlein said. What works for one person at a certain point in their menstrual cycle might not work for someone else. Schoeberlein hopes the results can act as another tool in athletes' toolboxes and empower them to push themselves. "How you feel still matters, but don't limit yourself," she said. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A study from researchers at the CU Anschutz Marcus Institute for Brain Health suggests that veterans with concussions may continue to show subtle but measurable brain function differences more than a decade after their injury. Researchers found these differences can be detected through specialized eye movement testing. While most individuals recover within weeks or months, the new research indicates that some may experience lingering changes in attention, processing speed and impulse control long after symptoms appear to resolve. The eyes are directly connected to brain networks that control attention, information processing and decision-making. By studying how someone's eyes move during a cognitively demanding task, we can detect subtle brain changes that might not appear on a standard bedside exam or brain scan." Jeffrey Hebert, PhD, PT, study's lead investigator, associate professor at the CU Anschutz School of Medicine and director of research for the CU Anschutz Marcus Institute for Brain Health The study evaluated 78 military veterans, including 38 with a history of mild traumatic brain injury and 40 without. Some of these differences were still measurable more than 10 years after the original injury. Hebert said eye movements rely on complex networks across multiple regions of the brain. Because these processes depend on widespread neural connections, several mild injuries may leave lasting but difficult to detect effects. "Even when someone feels recovered, their brain may still be working differently behind the scenes, especially during visually demanding tasks and in busy environments" Hebert said. "Objective eye movement testing gives us a measurable way to assess these often covert problems." The findings could have important implications for long term concussion care. "Standard imaging tools such as MRI scans often appear normal after mild brain injury, making persistent symptoms difficult to verify objectively," Hebert said. "Cognitively challenging eye movement assessments may provide clinicians with an additional tool to better understand ongoing cognitive concerns and more precisely tailor rehabilitation strategies. The team emphasizes that most individuals recover well from mild traumatic brain injury. However, identifying those who continue to experience subtle effects could improve follow up care, long term monitoring and treatment planning optimizing healthier brain adaptation. Future studies will explore whether incorporating cognitively challenging eye movement testing into routine concussion evaluations could help clinicians better identify traumatic brain injury, track recovery and guide treatment decisions. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Please do not ask questions that use sensitive or confidential information.